M Heywood|P Noakes - JoVE Visualize

Showing results (41-50 of 59) with videos related to

Pageof 6

Sort By:

Biochemical Pharmacology|November 15, 1990

Beta-adrenoceptors and the effect of beta-agonists on protein metabolism in ovine primary muscle culturesM E Symonds, J A Roe, C M Heywood, et al.

Gynecologic Oncology|March 1, 1992

Glassy cell carcinoma of the cervix: a bimodal treatment strategyR J Lotocki, G V Krepart, M Paraskevas, et al.

Stroke|April 1, 1997

Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortalityD M Heywood, A M Carter, A J Catto, et al.

Annals of the Royal College of Surgeons of England|July 1, 1997

Randomised trial of subcuticular suture versus metal clips for wound closure after thyroid and parathyroid surgeryD Selvadurai, C Wildin, G Treharne, et al.

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 20, 2005

Maternal reactivity to fetal alloantigens is related to newborn immune responses and subsequent allergic diseaseS L Prescott, A Taylor, J Roper, et al.

Journal of Magnetic Resonance Imaging : JMRI|January 1, 1993

Primary ovarian cancer: prospective comparison of contrast-enhanced CT and pre-and postcontrast, fat-suppressed MR imaging, with histologic correlationR C Semelka, P H Lawrence, J P Shoenut, et al.

Resuscitation|September 3, 2013

Characteristics and outcome of patients with DNACPR orders in an acute hospital; an observational studyZoë B McC Fritz, Richard M Heywood, Suzanne C Moffat, et al.

American Journal of Hospital Pharmacy|May 1, 1988

Improved reporting of adverse drug reactionsB J Kimelblatt, S H Young, P M Heywood, et al.

Current Oncology (Toronto, Ont.)|April 21, 2011

Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21H J Mackay, D Provencheur, M Heywood, et al.

Molecular Cancer Therapeutics|July 15, 2004

Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the ratSteve A Horner, Sarah Gould, James P Noakes, et al.

Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:

Pageof 6

Biochemical Pharmacology|November 15, 1990

Beta-adrenoceptors and the effect of beta-agonists on protein metabolism in ovine primary muscle culturesM E Symonds, J A Roe, C M Heywood, et al.

Gynecologic Oncology|March 1, 1992

Glassy cell carcinoma of the cervix: a bimodal treatment strategyR J Lotocki, G V Krepart, M Paraskevas, et al.

Stroke|April 1, 1997

Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortalityD M Heywood, A M Carter, A J Catto, et al.

Annals of the Royal College of Surgeons of England|July 1, 1997

Randomised trial of subcuticular suture versus metal clips for wound closure after thyroid and parathyroid surgeryD Selvadurai, C Wildin, G Treharne, et al.

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 20, 2005

Maternal reactivity to fetal alloantigens is related to newborn immune responses and subsequent allergic diseaseS L Prescott, A Taylor, J Roper, et al.

Journal of Magnetic Resonance Imaging : JMRI|January 1, 1993

Primary ovarian cancer: prospective comparison of contrast-enhanced CT and pre-and postcontrast, fat-suppressed MR imaging, with histologic correlationR C Semelka, P H Lawrence, J P Shoenut, et al.

Resuscitation|September 3, 2013

Characteristics and outcome of patients with DNACPR orders in an acute hospital; an observational studyZoë B McC Fritz, Richard M Heywood, Suzanne C Moffat, et al.

American Journal of Hospital Pharmacy|May 1, 1988

Improved reporting of adverse drug reactionsB J Kimelblatt, S H Young, P M Heywood, et al.

Current Oncology (Toronto, Ont.)|April 21, 2011

Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21H J Mackay, D Provencheur, M Heywood, et al.

Molecular Cancer Therapeutics|July 15, 2004

Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the ratSteve A Horner, Sarah Gould, James P Noakes, et al.

Pageof 6